Search This Blog

Wednesday, May 29, 2024

An Older, Anxious, Mildly Paranoid Analyst

 By Michael Every of Rabobank

An older, anxious, mildly paranoid analyst

US Treasury yields spiked higher yesterday after strong consumer confidence data and weak bond auctions, pushing the dollar up. The Fed’s Kashkari said the FOMC hasn’t entirely ruled out further rate hikes, but the odds are “quite low”. But how does one assess the risks of a shock like that? Market pricing just shows you what all uniformed people think, so zooms around wildly, e.g., shifting expectations for 2024 rate cuts over the past six months. Data means you have to forecast them right. Fundamentals, perhaps – but which? And, ultimately, fundamental psychology.

On which, because I don’t get all my news from financial or mainstream media --a deliberate epistemology-- I stumbled on a report for the Israeli army by psychologist Ofer Grosbard explaining why it disastrously failed to anticipate October 7. It applies equally to those who didn’t expect Russia to invade Ukraine, and to a host of other problems right in front of us now.

In summary, Israeli intelligence was too optimistic. They ignored repeated warning signs, including a copy of the Hamas invasion plan, believing Hamas didn’t mean it or had no desire or ability to attack. That should be clear unless you believe in conspiracy theories, so need a psychiatrist.

The follow-on conclusion is intelligence services --and those running market risk-- need experts who can spot patterns or subtle clues of possible emerging threats in geopolitics, human behavior and psychology. That’s clear.

However, data show older, pessimistic, and anxious, mildly paranoid or mildly depressed people are better placed for this kind of thinking as their outlook is more analytical and “fosters a heightened sense of vigilance” and “a cautious approach, ensuring all possibilities, no matter how unlikely, are considered and prepared for.” By contrast, younger optimists say, “Buy all the things,” or “rate cuts!”, or “I see no ships.”

Crucially, however, most institutions promote the assertive, confident, and optimistic to senior roles: then hubris meets nemesis. One hopes new Dutch Prime Minister (Hendrikus Wilhelmus Maria) Dick Schoof, with an intelligence background, is a gloomy individual.

Would he have predicted risks to “rate cuts!” optimism now repeated in a Financial Times deep-dive into the Deep Ship EU ports are in due to the Houthi Suez Canal blockade? As we said months ago, if West Med ports run at 100% capacity as trans-shipment conduits to the East Med in peak pre-Xmas retail season, firms build higher inventories to compensate for longer delivery times, and consumer spending picks up as rates fall -- that first ECB cut is in June -- then supply-side inflation shocks can be expected. Things may also get worse as Israel enters the heart of Rafah, the Houthis try to hit the East Med, Iran is closer to a nuke, and the $320m Biden Gaza aid pier drifts off and breaks apart, a metaphor for the how the broader region sees the US.

In Australia, with reluctant RBA talk of another rate hike, April monthly CPI weighted to goods was 3.6% y-o-y vs. 3.4% consensus and 3.5% in March. Housing was 4.9% with rents 7.5%; food and beverages 3.8%; alcohol and tobacco 6.5%; transport 4.2% with fuel 7.4%; insurance and financial services 8.2%, education 5.2%, and only holidays -6.2%: if you don’t eat or drive on one. Our house forecast is two more hikes unless the RBA is hoodwinked by the budget artificially supressing CPI with subsidies. Which, optimists will say is the case: the market is only pricing around a 25% chance of a September rate hike despite inflation well over the 2-3% target, a stimulatory budget, and the global backdrop being inflationary again, not disinflationary.

But do you really need to be older, pessimistic, anxious, mildly paranoid or mildly depressed to see how large the structural problems that we face are?

In the UK, one headline just said, ‘Rishi Sunak winning back 2019 Tory voters after announcing snap election’. The polls say it’s 2,019 Tory voters. The Labour Party, with “secureonomics” at its pledge, is ruling out further tax increases after extending the windfall tax on energy companies’ profits, imposing VAT on private school fees, and ensuring private equity bonuses are “taxed appropriately”. Yet it faces a large fiscal deficit and wants to spend more to transform the UK economy: something doesn’t add up. One hopes for the best, but paranoid political risk types are not looking at the upcoming election, which seems a given, but at the one after that; they are wondering what the backlash to a failed Labour government might look like, as well as how far right the post-defeat Tories shift.

In the US, all eyes are on the New York court that is likely the only Donald Trump trial that will come to a conclusion before the November election – and as many legal and political commentators have pointed out, it’s been a clown show likely to be turned over on appeal even if a guilty verdict is returned, and which has boosted Trump’s electoral prospects. Those of a more paranoid mindset had thus correctly already been factoring in what hypothetical higher US tariffs might mean for inflation and the world economy.

In Canada, we got a headline which runs true everywhere in the West, and much of the world outside China: ‘Trudeau says real estate needs to be more affordable, but lowering home prices would put retirement plans at risk’. Yes, homes need to be more affordable. No, prices can’t come down, “because Boomers.” Can rates come down? No, “because inflation” and “further house-price inflation.” Can wages go up? NO! “Because inflation > rates > Boomers > markets.”

Let’s be frank: thinking high house prices were a good way to juice the economy was an idiot plan at its inception to those with functioning brains, not just ones with mild paranoia or depression. The socioeconomic-political (neo-feudal) and geopolitical trends emerging because young, idiot, optimist economists didn’t tell their bosses those risks when they started to blow this bubble are now enough to give everyone severe paranoia and depression. For example, Al Qaeda are expressing their appreciation to Western Ivy League student protestors, after Osama Bin Laden went viral on TikTok a few months ago. They might even pick up a percentage of the vote if they ran in some countries’ elections.

Then again, are we surprised no optimistic young economists told their bosses not to juice house prices (again) when the American Economic Review reviews the reproducibility of 17 of its own papers from 2013 onwards, and finds that “many of the results are not robust, with no improvement over time”, while “a sample of economists (n=359) overestimates robustness reproducibility, but predictions are correlated with observed reproducibility.” In other words, economists believe their own hype even when they can’t reproduce any of the ‘results’ they claim. Then those same individuals set policy for governments or central banks.

And where economics meets national security, some in China are pushing it to adopt a Green Marshall Plan to deal with its overcapacity by sending vast sums to the Global South to accelerate transition, which could be transformative for the global economy, if it happens. By contrast, parts of the West are excited about an ECB rate cut in eight days, and Germany is --again-- backing off any serious martial plan even as it gets marginally cheaper to fund: it now won’t be adopting conscription after all. Because the other side has no desire or ability to fight, right?

It gives me no pleasure to say I tick all the Grosbard boxes for the characteristics needed for better risk analysis methodology; but then not getting a lot of pleasure from things is sadly part of the whole deal.

https://www.zerohedge.com/markets/older-anxious-mildly-paranoid-analyst

Jury Begins Deliberations In Trump 'Hush Money' Trial

 With closing arguments in Donald Trump's hush money trial having ended on Tuesday, jury deliberations have officially begun, putting the outcome of the case in the hands of a dozen New Yorkers.

A jury of seven men and five women were instructed to begin deliberating just before 11:30 a.m., where they will weigh in on the first criminal trial of a former US president. While the jurors' discussions will be in private, they can send Trump-hating Judge Juan Merchan notes asking to rehear testimony or review evidence.

"It is not my responsibility to judge the evidence here. It is yours," said Merchan.

Trump is charged with 34 counts of falsifying business records in connection with an alleged scheme to shelve potentially embarrassing claims during the 2016 US election - similar to how the Clintons paid Paula Jones $850,000 to drop a sexual harassment lawsuit after more than four years of legal action.

According to Merchan, "Your verdict on each count you consider, whether guilty or not, must be unanimous," adding "That is, each and every juror must agree to it."

"You should discuss the evidence and consult with each other, listen to each other, give each other's views careful consideration. And when you deliberate, you should do so with a view to reaching agreement when that can be done without surrendering an individual juror," Merchan continued.

As the Epoch Times notes further, all the evidence from trial has been loaded onto a laptop, and Juror 4 and Juror 6 volunteered to operate it for the group.

Merchan checked with defense attorney Todd Blanche about whether defense counsel explained to President Trump about evidence being on the laptop for jurors.

Mr. Blanche affirmed that defense counsel reviewed the contents of the laptop and have no objections to this protocol.

"I always watch the jurors. I watch to see who is paying attention and who is not," said Merchan. "Justice Merchan said. "Each of you is very engaged in this case. But we're not going to excuse [alternates]."

During closing arguments on Tuesday, Merchan criticized Blanche for telling the jury that the former president could go to prison if they convict - and reminded them that their decision would be based on the word of Michael Cohen, who Blanche described as a "liar" who "lied to" the jury.

"You cannot send somebody to prison, you cannot convict somebody based upon the words of Michael Cohen," said Blanche - to which prosecutors jumped in and objected.

Merchan agreed, sustaining the objection.

"That was outrageous, Mr. Blanche," he said. "Someone who’s been a prosecutor as long as you have, someone who’s been an attorney as long as you have knows that it’s highly inappropriate."

https://www.zerohedge.com/political/jury-begins-deliberations-trump-hush-money-trial


Bristol stakes $80m on Prothena’s neurodegenerative candidate

 Five months after being cleared for clinical trials, the global licence for Prothena’s neurodegenerative disease treatment candidate PRX019 has been picked up by Bristol Myers Squibb (BMS) for $80m.

The deal for the asset also includes an additional $617.5m in additional development, regulatory, and sales milestone-related payments, as well as royalties, as per a 28 May press release by Prothena.

The two companies have neither disclosed the modality of PRX019 nor the intended indication within the neurodegenerative disease space.

The US Food and Drug Administration (FDA) greenlit the drug for use in clinical trials in December 2023, with Ireland-based Prothena saying it now plans to initiate a Phase I clinical trial with the drug by the end of this year.

BMS’ Neuroscience Thematic Research Center head Richard Hargreaves said: “Through our partnership with Prothena, we have identified and advanced PRX019 as a potential disease-modifying treatment option for patients suffering from neurodegenerative diseases.”

Hargreaves said that asset adds to BMS’ “growing neuroscience pipeline.”

The licence deal for PRX019 is not the first time BMS and Prothena have worked together. BMS bought the US licence for Prothena’s PRX-005 for $80m in June 2021. This was followed by a worldwide licence for the same drug for $55m in October 2023. The candidate, now called BMS-986446, is in a Phase II trial for Alzheimer’s disease.

BMS made no secret of its neuroscience push when it acquired drugmaker Karuna Therapeutics for a colossal $14bn in March. With the deal, BMS acquired Karuna’s schizophrenia drug-in-waiting KarXT. Also transferred to BMS’ pipeline were candidates for Alzheimer’s-related psychosis and mood disorders.

The upfront payments in the latest deal will be important for Prothena, who reported a net loss of $147m for the full year of 2023, more than the $116.9m loss it incurred in 2022. The biotech cited higher R&D and G&A expenses in 2023 compared to the previous year.

Prothena’s most advanced candidate is monoclonal antibody, birtamimab, is currently in a Phase III clinical trial for the treatment of AL amyloidosis. The therapy has been awarded FDA orphan drug status and fast track designation.

https://finance.yahoo.com/m/37c93a2c-9f0b-39fb-bedb-6394e24cc17a/bms-stakes-%2480m-on-prothena%E2%80%99s.html

J&J's depression treatment succeeds in late-stage study

 Johnson & Johnson said on Wednesday its experimental drug helped reduce symptoms of major depressive disorder (MDD) and insomnia in a late-stage trial when given along with commonly used antipsychotic treatments.

The drug candidate known as seltorexant was administered to adult and elderly patients assessed to be moderate to severely depressed despite ongoing treatment with antidepressants and suffered from significant sleep disturbance.

MDD is one of the most common chronic mental disorders in the United States, according to the National Institutes of Health.

J&J's drug candidate met both main and secondary trial goals, showing improvement in depressive symptoms when tested on a scale used to measure the severity of depressive episodes and also improved sleep disturbance outcomes in patients.

The drugmaker said seltorexant was also safe and well-tolerated in the study, with similar rates of common adverse events seen in both trial arms, consistent with previous trials.

Seltorexant works by selectively targeting proteins known as orexin-2 receptors, which play a key role in sleep-wake rhythm of the body.

When orexin-2 receptors are stimulated for too long, their activation can cause a group of symptoms, including excessive cortisol release, which may contribute to depression and insomnia.

About 21 million adults in the United States had at least one episode of major depressive disorder in 2021, according to government estimates.

The mood disorder's symptoms include sadness, helplessness and feelings of guilt, and it is often accompanied by sleep disturbances such as insomnia that exacerbate the risk of depressive relapse, increase healthcare costs and impact quality of life.

With currently no therapies approved to treat the disease, 60% of MDD patients on standard-of-care oral antidepressants experience residual insomnia symptoms, the company said in a statement.

https://www.yahoo.com/news/j-js-treatment-depression-succeeds-121216360.html

Sage started at Sell by Citi, Neutral by Baird

 

TodayInitiatedRobert W. BairdNeutral$15
TodayInitiatedCitigroupSell$8

UnitedHealth stock falls as it sees 'disturbance' in Medicaid business

 UnitedHealth Group (NYSE:UNH) shares tumbled as much as 6% Wednesday after an unnamed executive at the company said they see "disturbance" coming in the firm's Medicaid business.

The comments at the Bernstein 40th Annual Strategic Decisions Conference have also resulted in a decline for other health insurance companies. Centene (NYSE:CNC) declined around 6.3%, while Molina Healthcare (NYSE:MOH) fell 6.5%. Humana (NYSE:HUM) shares dropped 5% while sank Elevance as much as 4%

The company's participants at the conference included CEO Andrew Witty. An executive at UNH touched on Medicaid, stating that they have come through this "very sort of prolonged redetermination cycle."

He added the company has been making sure "the utilization and the rates and everything else stay in perfect synchrony through a multi-quarter cycle."

However, "there's probably going to be some disturbance around that," he said, adding that they are watching it and that Medicaid is an area the company is focused on.

Heather Cianfrocco, the CEO of UnitedHealth's Optum Rx subsidiary, commented that commercial and Medicaid "continue to be a focus for us, but it tends to be geographically specific and employer-specific."

https://www.investing.com/news/stock-market-news/unitedhealth-stock-falls-as-it-sees-disturbance-in-medicaid-business-432SI-3461266

Biohaven Crashes After Protein-Degrading Drug Misses Expectations

 Biohaven (BHVN) stock crashed Wednesday after the company's experimental protein-degrading drug — which could be used to treat a myriad of immune-related diseases — lagged investor expectations.

The company tested four doses of its drug, BHV-1300, which is meant to break down immunoglobulin G, or IgG, an autoantibody at the center of diseases like rheumatoid arthritis and myasthenia gravis. In healthy volunteers, the doses reduced IgG by up to 37%.

Biohaven called the results "positive," noting that IgG levels began to fall without hours of treatment. But the results fell far short of expectations for 60% lower IgG levels, William Blair analyst Tim Lugo said in a report. Biohaven is going up against Argenx (ARGX) and Immunovant (IMVT) in this space.

https://www.investors.com/news/technology/biohaven-stock-protein-degrading-drug-argenx-immunovant/